Results 151 to 160 of about 13,127 (167)

Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir [PDF]

Antiviral Research, 2016
Favipiravir, a viral RNA-dependent RNA polymerase inhibitor, has recently been approved in Japan for influenza pandemic preparedness. Here, we conducted a cell-based screening system to evaluate the susceptibility of influenza viruses to favipiravir.
Yoshihiro Kawaoka, Gabriele Neumann, Masato Tashiro   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

EBioMedicine, 2021
Lana Langendries, Judith Breuer, Xin Zhang   +2 more
exaly  

Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial

European Journal of Pharmaceutical Sciences, 2021
Hang-Ping Yao, Yan Lou, Xiaoyang Lu
exaly  

Spectrofluorimetric quantitative analysis of favipiravir, remdesivir and hydroxychloroquine in spiked human plasma

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2022
Sherif Ramzy, Mohamed A Hasan, Ahmed H Abdelazim   +2 more
exaly  

Favipiravir, an anti-influenza drug against life-threatening RNA virus infections

Pharmacology & Therapeutics, 2020
Kimiyasu Shiraki, Tohru Daikoku
exaly  

Development and validation of a sensitive, fast and simple LC-MS / MS method for the quantitation of favipiravir in human serum

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021
Duygu Eryavuz Onmaz, Sedat Abusoglu, Fatma Hümeyra Yerlikaya   +2 more
exaly  

A density functional theory study on favipiravir drug interaction with BN-doped C60 heterofullerene

Physica E: Low-Dimensional Systems and Nanostructures, 2022
Mustaf Kurban, İskender Muz, Fahrettin Goktas   +2 more
exaly  

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

International Journal of Infectious Diseases, 2021
Saiprasad Patil, Hanmant Barkate, Amol Pendse   +2 more
exaly  

Favipiravir: insight into the crystal structure, Hirshfeld surface analysis and computational study

Journal of the Iranian Chemical Society, 2021
Maria G Babashkina, Damir A Safin
exaly  

Favipiravir for symptomatic COVID-19: A nationwide observational cohort study

Journal of Infection and Chemotherapy, 2023
Takuma Ishihara, Yohei Doi, Masahiko Ando   +2 more
exaly